Aberdeen discloses 4.16% stake in Quoin Pharmaceuticals

Aberdeen Group plc reports beneficial ownership of 75,000 American Depositary Shares (ADS) of Quoin Pharmaceuticals, Ltd., representing 4.16% of the ADS class.

Rhea-AI Filing Summary

Aberdeen Group plc reports beneficial ownership of 75,000 American Depositary Shares (ADS) of Quoin Pharmaceuticals, Ltd., representing 4.16% of the ADS class. Each ADS represents 35 ordinary shares.

The filing lists Aberdeen Group plc as the parent, with abrdn Inc. holding shared voting and dispositive power over the 75,000 ADS on behalf of underlying clients. Signatures are dated 04/29/2026.

Insights

Institutional Ownership Analyst

Large asset manager reports a sub-5% passive stake in QNRX.

The schedule shows 75,000 ADS (4.16%) held with shared voting and dispositive power by abrdn Inc., consistent with an institutional, client-account holding. The ADS ratio (35 ordinary shares per ADS) is stated explicitly.

Impact is routine: this filing documents ownership levels and control structure; subsequent filings would show any material changes in stake or voting arrangements.

Registry & Compliance Specialist

Amendment clarifies parent/subsidiary attribution and ownership classification.

The exhibit identifies Aberdeen Group plc as parent and abrdn Inc. as intermediary, noting holdings are on behalf of underlying clients. Item 5 confirms the position is an ownership of 5 percent or less of the class.

Filing functions as a transparency/update filing; watch for future amendments if the stake crosses reporting thresholds.

Key Figures

Beneficial ownership: 75,000 ADS Percent of class: 4.16% ADS ratio: 1 ADS = 35 ordinary shares +1 more

4 metrics

Beneficial ownership 75,000 ADS Amount beneficially owned reported in Item 4

Percent of class 4.16% Percent of ADS class reported in Item 4

ADS ratio 1 ADS = 35 ordinary shares Title describes ADS representation

Signature date 04/29/2026 Dates on signed amendment

Key Terms

American Depositary Shares (ADS), Beneficially owned, Shared Dispositive Power, Schedule 13G/A

4 terms

American Depositary Shares (ADS) financial

"American Depositary Shares, each representing Thirty-five (35) Ordinary Shares"

American depositary shares (ADS) are a way for investors in the United States to buy shares of foreign companies without dealing with the complexities of international markets. They represent ownership in a foreign company's stock and are traded on U.S. exchanges, making it easier and more convenient for Americans to invest internationally. ADSs allow investors to diversify their portfolios with foreign companies while using familiar trading platforms.

Beneficially owned regulatory

"Amount beneficially owned: 75,000"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared Dispositive Power regulatory

"Shared Dispositive Power 75,000.00"

Schedule 13G/A regulatory

"(Amendment No. 1 ) Quoin Pharmaceuticals, Ltd."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Aberdeen report in QNRX (Quoin Pharmaceuticals)?

Direct answer: Aberdeen reports beneficial ownership of 75,000 ADS, equal to 4.16% of the ADS class. Context: The filing states each ADS represents 35 ordinary shares and attributes shared voting and dispositive power to abrdn Inc.

Who holds voting and dispositive power for the reported QNRX shares?

Direct answer: The filing shows shared voting and shared dispositive power of 75,000 ADS held by abrdn Inc. Context: Aberdeen Group plc is listed as the parent and abrdn Inc. as the intermediary holding entity.

Does this Schedule 13G/A indicate active control or an investment stake?

Direct answer: The filing documents a passive beneficial ownership stake of 4.16% rather than a controlling position. Context: Item 5 labels the position as ownership of 5 percent or less of the class and shows shared power held for client accounts.

What ADS-to-ordinary share ratio is disclosed in the filing for QNRX?

Direct answer: The filing states each ADS represents 35 ordinary shares. Context: That ratio appears on the cover description for the American Depositary Shares class being reported.

When was the Schedule 13G/A amendment signed?

Direct answer: The signatures on the amendment are dated 04/29/2026. Context: The document header also shows a date line of 04/01/2026 adjacent to the ADS cover description.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 06:41 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Quoin Pharmaceuticals, Ltd.

(Name of Issuer)

American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share

(Title of Class of Securities)

74907L409

(CUSIP Number)

04/01/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 74907L409

1

Names of Reporting Persons

Aberdeen Group plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 75,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 75,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

75,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.16 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 74907L409

1

Names of Reporting Persons

abrdn Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 75,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 75,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

75,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.16 %

12

Type of Reporting Person (See Instructions)

CO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quoin Pharmaceuticals, Ltd.
(b)	Address of issuer's principal executive offices: 23 HATA'AS STREET, KFAR SABA, ISRAEL 44425
Item 2.
(a)	Name of person filing: Aberdeen Group plc abrdn Inc.
(b)	Address or principal business office or, if none, residence: Aberdeen Group plc 1 George Street Edinburgh, United Kingdom EH2 2LL abrdn Inc. 1900 Market Street Suite 200, Philadelphia, PA 19103
(c)	Citizenship: Aberdeen Group plc - UNITED KINGDOM abrdn Inc. - UNITED STATES
(d)	Title of class of securities: American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share
(e)	CUSIP No.: 74907L409
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 75,000
(b)	Percent of class: 4.16 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Aberdeen Group plc - 0 abrdn Inc. - 0
	(ii) Shared power to vote or to direct the vote: Aberdeen Group plc - 75,000 abrdn Inc. - 75,000
	(iii) Sole power to dispose or to direct the disposition of: Aberdeen Group plc - 0 abrdn Inc. - 0
	(iv) Shared power to dispose or to direct the disposition of: Aberdeen Group plc - 75,000 abrdn Inc. - 75,000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aberdeen Group plc

Signature:	Cara Bird
Name/Title:	Cara Bird/Major Shareholding Reporting Analyst
Date:	04/29/2026

abrdn Inc.

Signature:	Cara Bird
Name/Title:	Cara Bird/Major Shareholding Reporting Analyst
Date:	04/29/2026

Exhibit Information

Aberdeen Group plc abrdn Holdings Limited abrdn Inc. Aberdeen Group plc is the parent company. abrdn Holdings Limited is the intermediate holding company for abrdn Inc. abrdn Inc. beneficially owns on behalf of our underlying clients less than 5% of the outstanding shares of the security class being reported on this Schedule 13G.